Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athersys Inc ATHXQ

Healthcare Biotechnology
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company’s operations consist of research, clinical development activities, manufacturing and an advanced program in a pivotal Phase 3 clinical trial for the treatment of ischemic stroke. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead... see more

Recent & Breaking News (GREY:ATHXQ)

The Vatican's Pontifical Council for Culture, NeoStem, The Stem for Life Foundation & STOQ International Host 2nd International Vatican Adult Stem Cell Conference

Globe Newswire April 11, 2013

Athersys to Present at Regen Med Investor Day 2013 in New York

Globe Newswire April 11, 2013

Publications Demonstrate Relevance of MultiStem(R) for Autoimmune Disease, Transplantation and Vascular Disease

Globe Newswire April 10, 2013

Free Research Reports on ATHX, HIMX, SIG and VRNG Issued by the Bedford Report

Marketwired April 1, 2013

The Vatican's Pontifical Council for Culture, NeoStem, The Stem for Life Foundation & STOQ International Announce Highlights of the Upcoming Second International Adult Stem Cell Conference

Globe Newswire March 22, 2013

Biotech Industry Looks to Benefit From FDA's New "Breakthrough" Designation

Marketwired March 18, 2013

Athersys Reports Fourth Quarter and 2012 Annual Results

Troy Schwensen March 12, 2013

Athersys to Host Fourth Quarter and Year-End 2012 Financial Results Call

Troy Schwensen February 25, 2013

Athersys Announces Adjournment of Special Meeting Date

Troy Schwensen February 21, 2013

Athersys to Present at New York Stem Cell Summit '13

Troy Schwensen February 13, 2013

U.S. Food and Drug Administration Approved 30% More Drugs in 2012

Marketwired February 12, 2013

Athersys to Present at BIO CEO & Investor Conference

Troy Schwensen February 11, 2013

Free Research Reports on APPY, ATHX, CLSN and DCTH Issued by the Bedford Report

Marketwired February 5, 2013

Record Levels of Available Cash and Moderate R&D Development Will See Big Pharma M&A Activity Increase in 2013

Marketwired January 22, 2013

Athersys Files Shelf Registration to Replace Expiring S-3 Registration Statement

Troy Schwensen January 11, 2013

Athersys to Present at Biotech Showcase(TM) 2013

Troy Schwensen January 7, 2013